Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366048 | 0.72 | — | — | |
| SCHEMBL14841196 | 0.72 | CA12 (0.46) | CA12CA1CA2CA9 | |
| SCHEMBL29412512 | 0.72 | CA12 (0.32) | CA12CA1CA2CA9 | |
| SCHEMBL21550863 | 0.68 | — | — | |
| SCHEMBL11712850 | 0.68 | — | — | |
| Quinoxaline SCHEMBL27480152 | 0.67 | ALDH1A1 (0.31) | — | |
| Pyrazine SCHEMBL28762530 | 0.67 | MAPT (0.31) | — | |
| SCHEMBL30417888 | 0.67 | NOS3 (0.32) | CA12CA1CA2CA9 | |
| SCHEMBL8924 | 0.66 | MAPT (0.37) | — | |
| SCHEMBL3662203 | 0.66 | MAPT (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 272 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114341127-B | Aminopyrazine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-12-17 | — | — | CN | claimed |
| WO-2024246946-A1 | NOVEL PYRIDINE CARBOXAMIDE COMPOUNDS WITH ANTI-TUBERCULAR ACTIVITY | TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE (IN) | 2024-12-05 | — | — | WO | claimed |
| US-20220289712-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2022-09-15 | — | — | US | claimed |
| CN-114341127-A | Aminopyrazine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2022-04-12 | — | — | CN | claimed |
| US-20210353627-A1 | NOVEL QUINAZOLINE EGFR INHIBITORS | SPECTRUM PHARMACEUTICALS, INC. | 2021-11-18 | — | — | US | claimed |
| EP-3852762-A1 | NOVEL QUINAZOLINE EGFR INHIBITORS | Spectrum Pharmaceuticals, Inc. (US) | 2021-07-28 | — | — | EP | claimed |
| CN-113056272-A | Novel quinazoline EGFR inhibitors | 光谱医药公司 | 2021-06-29 | — | — | CN | claimed |
| WO-2021032148-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2021-02-25 | — | — | WO | claimed |
| WO-2020061470-A1 | NOVEL QUINAZOLINE EGFR INHIBITORS | SPECTRUM PHARMACEUTICALS, INC. (US) | 2020-03-26 | — | — | WO | claimed |
| EP-2221302-B1 | Pyrido-oxazine-based monomer, polymer thereof, electrode for fuel cell including the polymer, electrolyte membrane for fuel cell including the polymer, and fuel cell using the electrode | SAMSUNG ELECTRONICS CO LTD (KR) | 2012-03-21 | — | — | EP | claimed |
| EP-0468258-B1 | Substituted pyrido-oxazines | BAYER AG (DE) | 1995-11-02 | — | — | EP | claimed |
| US-5137881-A | Anticholesterol, antilipemic agents | BAYER AKTIENGESELLSCHAFT (DE) | 1992-08-11 | — | — | US | claimed |
| EP-0468258-A1 | Substituted pyrido-oxazines | BAYER AG (DE) | 1992-01-29 | — | — | EP | claimed |
| US-5059605-A | Methyl 2-(pyridyloxypyrimidinyleneoxyphenylene)-3-methoxypropenoates | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-10-22 | — | — | US | claimed |
| JP-61097291-A | — | — | None | — | — | JP | disclosed |
| EP-4717266-A2 | OCTAHYDRO FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therapeutics Incorporated (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4097111-B9 | PYRIDO[2,3-E]OXAZINE DERIVATIVES AS AGRICULTURAL CHEMICALS | GLOBACHEM NV (BE) | 2025-10-29 | — | — | EP | disclosed |
| US-4324893-A | 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-04-13 | — | — | US | disclosed |
| EP-0018735-A1 | 1,8-Naphthyridine derivatives, their preparation, pharmaceutical compositions containing them | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-11-12 | — | — | EP | disclosed |
| WO-1980002287-A1 | 1,8-NAPHTHYRIDINE DERIVATIVES | AMERICAN HOME PROD (US) | 1980-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289712-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | MAPKAPK5, STK25, STK35 | CA12 4597/4885CA1 4519/4885CA2 3227/4885 |
| US-20210353627-A1 | NOVEL QUINAZOLINE EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | CA12 4398/4885CA1 4779/4885CA2 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.